If plasma biomarker results are entered, the risk estimates generated from the parsimonious models are shown, with the choice to use GFAP, or alternatively pTau217 results to determine the risk of progression to any-cause dementia, and GFAP and pTau181 to determine the risk of progression to AD dementia (Fig. 2b). This evidence concerns the gene GFAP and dementia.